Article
Industry Challenges Contribute to Financial Toxicity
In this third panel discussion from ONS’s Health Policy Summit in Washington DC, Alan Balch, PhD, Patient Advocate Foundation chief executive officer, Mike Ybarra, MD, FAAEM, FACEP, vice president of medical affairs for the Pharmaceutical Research Manufacturers Association, and Jeannine Walston, a 20-year brain cancer survivor and patient advocate, discuss the challenges of tackling financial toxicity from an industry perspective, how nurses can advocate for patient resources, and much more.
Related Topics
You May Also Like
Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
Article